NANOSMARTS

Smart nondimensional biosensors for detection of tumor cells and cytotoxic amyloids intermediates

 Coordinatore MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. 

 Organization address address: Hofgartenstrasse 8
city: MUENCHEN
postcode: 80539

contact info
Titolo: Mr.
Nome: Manfred
Cognome: Messerschmidt
Email: send email
Telefono: -2011723
Fax: -2011833

 Nazionalità Coordinatore Germany [DE]
 Totale costo 156˙993 €
 EC contributo 156˙993 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2007-4-2-IIF
 Funding Scheme MC-IIF
 Anno di inizio 2008
 Periodo (anno-mese-giorno) 2008-09-01   -   2010-08-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.

 Organization address address: Hofgartenstrasse 8
city: MUENCHEN
postcode: 80539

contact info
Titolo: Mr.
Nome: Manfred
Cognome: Messerschmidt
Email: send email
Telefono: -2011723
Fax: -2011833

DE (MUENCHEN) coordinator 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

emission    proteins    biosensors    smaller    qds    probes    cells    drug    fluorescent    distinguish    binding    assays    dual    dyes    silicon    nm    protein    egfr    glioma    folding    aggregation    diseases    conjugated    tumor    nanoparticles    neurodegenerative   

 Obiettivo del progetto (Objective)

'This project integrates the development of (a) bioconjugated silicon nanoparticles (NPs) as new, < 3nm, fluorescent probes and (b) dual-emission band fluorescent biosensors for protein conformation investigations to be applied in diagnostic procedures related to tumor biology and neurodegenerative diseases. Epidermal growth factor receptor (EGFR) is an important therapeutic target in a variety of tumors, particularly malignant gliomas where mutation and/or amplification of EGFR is often observed. The laboratory has demonstrated in a pilot study the specific binding of biomolecules conjugated to Quantum Dots to patient-derived glioma spheroids. High wavelength emitting QDs are necessary to distinguish binding from tissue autofluorescence but such QDs are large (~40 nm) and do not penetrate deeply into tissues or access cellular junctions. The project will develop smaller, more inert, and less toxic conjugated silicon nanoparticles that can ultimately be used for the detection of residual glioma cells in patients after surgical resection. Additionally, more complex composite nanoparticles that selectively internalize in the tumor cells will be investigated as vehicles for drug delivery or selective killing. The aggregation of proteins and peptides is a fundamental feature of neurodegenerative diseases such as Alzheimer’s, Parkinson’s and spongiform encephalopathies. It is not clear whether the fibrillar aggregates or smaller forms of the implicated proteins are the cause of cytotoxicity. Both in vitro assays and in vivo studies are hampered by the lack of probes that can distinguish and quantitate early stages of the aggregation phenomenon. This project will develop fluorescent biosensors for protein folding on the basis of environment sensitive ratiometric dyes that exhibit dual emission. Such dyes are prospective tools for a development of facile and rapid assays for protein folding for application in diagnostics and drug screening assays.'

Altri progetti dello stesso programma (FP7-PEOPLE)

SEARCH (2010)

a Study of the Epigenetic Alterations that Result in Cardiac Hypertrophy

Read More  

TEAM (2009)

Training in European Asset Health Management

Read More  

ILSDD (2012)

Implicit Learning in Specific Developmental Disorders

Read More